Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

DUBLIN--()--The "CAR-T r/r CLL Global Market Forecast" report has been added to Research and Markets' offering.

Novel immune-therapeutic approaches in development for CLL include monoclonal antibodies, bi-specific antibodies, anti-PD1/PDL-1 checkpoint inhibitors, and the CAR-T cell therapies including JCAR014/JCAR017 (Juno Therapeutics), KTE-C19 (Kite Pharma), and CTL019 (tisagenlecluecel-T)(Novartis Pharmaceuticals). These potential CAR-T therapies or their next generations e.g. armoured' CARs and humanized versions are in development.

This product consists of a detailed Executive presentation (~130 slides, .pdf) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies in r/r CLL across 9 major Western markets to 2030.

A patient based flow methodology has been devised where possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of CLL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T CLL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.

Key Topics Covered:

1. Executive Summary

2. Car-T Treatment For R/R Cll - Commercial Model: Key Outputs

3. Chronic Lymphocytic Leukaemia - Disease Background

4. Chronic Lymphocytic Leukaemia - Epidemiology

5. Chronic Lymphocytic Leukaemia - Treatment

6. Novel Treatments For Cll - Immunotherapy Approaches

7. Novel Treatments For Cll - Modelling Commercial Potential Of Car-T Cell Therapies

8. Bibliography

Companies Mentioned

  • Axi-Cel
  • Juno Therapeutics Inc.
  • Kite Pharma/Gilead
  • Novartis

For more information about this report visit https://www.researchandmarkets.com/research/dwstnz/cart_rr_cll

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs